Argenica Therapeutics Limited (AGN) is actively engaged in pioneering research and development focused on neuroprotective therapeutic drugs. Their primary objective is to innovate novel treatments aimed at mitigating brain damage following stroke. By advancing these neuroprotective therapies, Argenica Therapeutics seeks to address critical needs in stroke care, potentially improving outcomes and quality of life for patients affected by this debilitating condition.